摘要
为探讨新型抗精神病药对精神分裂症复发的影响,采取随机抽样法,选取160例精神分裂症缓解期服用维思通做为维持治疗的患者进行2年的跟踪观察,并以同样的方法抽取160例精神分裂症缓解期服用氯氮平的患者做为对照组。结果,维思通总体复发率显著低于氯氮平组,两组在复发原因上也存在差异,另外,研究组比较或组间比较均有显著差异。结论:维思通对精神分裂症的长远疗效明显优于氯氮平,且依从性好,复发率低,社会功能受损小。
To explore the effect of new-type antipsychotics on relapse of schizophrenia, 160 patients who took risperidone as maintenance treatment during remission stage selected using random-sampling method weer followed up for 2 years and 160 ones who took clozapine as control group. Results: The total realapse rate of risperidone was lower than that of clozapine, and there was difference in relapse cause between the 2 groups. Conclusion: the long term effect of risperidone on schizophrenia was obviously better than that of clozapine, its complaince better, relapse rate lower and damage of social function mild.
